{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:33:53Z","timestamp":1793136833107,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.diabres.2026.113400","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:18:23Z","timestamp":1782656303000},"page":"113400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-9461","authenticated-orcid":false,"given":"Ashraf T.","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzia","family":"Alyafei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Tawfik","family":"Kardousha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayma","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alaaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-5285","authenticated-orcid":false,"given":"Noor","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.diabres.2026.113400_b0005","first-page":"1756","article-title":"Global prevalence of overweight and obesity in children and adolescents: a systematic review and meta-analysis","volume":"16","author":"Rocha","year":"2024","journal-title":"Nutrients"},{"issue":"Suppl 3","key":"10.1016\/j.diabres.2026.113400_b0010","first-page":"S29","article-title":"The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action","volume":"43","author":"Lobstein","year":"2019","journal-title":"Int J Obes (Lond)"},{"issue":"10481","key":"10.1016\/j.diabres.2026.113400_b0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Kerr","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0020","first-page":"37","article-title":"Current perspectives on management of type 2 diabetes in youth","volume":"8","author":"Singhal","year":"2021","journal-title":"Children (Basel)"},{"issue":"3","key":"10.1016\/j.diabres.2026.113400_b0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/dci22-0046","article-title":"Youth-onset type 2 diabetes: the epidemiology of an awakening epidemic","volume":"46","author":"Mayer-Davis","year":"2023","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.diabres.2026.113400_b0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","article-title":"Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012","volume":"376","author":"Mayer-Davis","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113400_b0035","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2026.113400_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113400_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.diabres.2026.113400_b0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study","volume":"20","author":"Kelly","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"22","key":"10.1016\/j.diabres.2026.113400_b0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2026.113400_b0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2026.113400_b0065","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113400_b0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113400_b0075","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for children 6 to <12 years of age with obesity \u2013 a randomized trial","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113400_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis","volume":"22","author":"Chadda","year":"2021","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0085","first-page":"462","article-title":"Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network meta-analysis","volume":"24","author":"Zhong","year":"2024","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.diabres.2026.113400_b0090","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese adolescents without diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.diabres.2026.113400_b0095","first-page":"208","article-title":"Efficacy of liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Cornejo-Estrada","year":"2023","journal-title":"Children (Basel)"},{"issue":"12","key":"10.1016\/j.diabres.2026.113400_b0100","first-page":"2793","article-title":"Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial","volume":"23","author":"Dixit","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0105","first-page":"398","article-title":"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis","volume":"23","author":"Le Bras","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"24","key":"10.1016\/j.diabres.2026.113400_b0110","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3390\/diagnostics14242829","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.diabres.2026.113400_b0115","first-page":"1287","article-title":"Characterizing GLP-1 receptor agonist use in preadolescent and adolescent populations","volume":"178","author":"Arslanian","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.diabres.2026.113400_b0120","doi-asserted-by":"crossref","DOI":"10.2217\/cer-2022-0187","article-title":"Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study","volume":"12","author":"Weghuber","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"5","key":"10.1016\/j.diabres.2026.113400_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics","volume":"14","author":"Mastrandrea","year":"2019","journal-title":"Pediatr Obes"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0130","first-page":"27","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists in overweight\/obese and\/or T2DM adolescents: a meta-analysis based on randomized controlled trials","volume":"17","author":"Chen","year":"2025","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"11","key":"10.1016\/j.diabres.2026.113400_b0135","first-page":"1870","article-title":"Systematic review and meta-analysis of liraglutide treatment in children who are overweight or obese: a therapeutic paradigm shift?","volume":"17","author":"Montemayor","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2026.113400_b0140","article-title":"Exenatide for obesity in children and adolescents: systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113400_b0145","article-title":"GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials","author":"Carvalho","year":"2025","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0150","article-title":"Pharmacological interventions for addressing pediatric and adolescent obesity: a systematic review and network meta-analysis","volume":"22","author":"Garcia-Hermoso","year":"2025","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113400_b0155","article-title":"The prevalence of the different components of the metabolic syndrome in obese nondiabetic children and young adolescents and their anthropometric data in relation to parents","volume":"92","author":"Soliman","year":"2021","journal-title":"Acta Biomed"},{"issue":"1","key":"10.1016\/j.diabres.2026.113400_b0160","first-page":"267","article-title":"Epidemiological criteria and risk factors for type two diabetes mellitus (T2DM) in children and adolescents: can we modify them?","volume":"16","author":"Soliman","year":"2022","journal-title":"World J Adv Res Rev"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:06:42Z","timestamp":1783458402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S0168822726003207"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113400","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113400"}}